SEARCH

SEARCH BY CITATION

References

  • Barks, J.H., Thompson, F.H., Taetle, R. et al. (1997). Increased chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in malignant melanoma. Genes Chromosomes Cancer 19, 278285.
  • Bastian, B.C., LeBoit, P.E., Hamm, H., Bröcker, E.B., and Pinkel, D. (1998). Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 58, 21702175.
  • Bastian, B.C., Olshen, A.B., LeBoit, P.E., and Pinkerl, D. (2003). Classifying melanocytic tumors based on DNA copy number changes. Am. J. Pathol. 163, 17651770.
  • Champoux, J.J., and Dulbecco, R. (1972). An activity from mammalian cells that untwists superhelical DNA – a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay). Proc. Natl. Acad. Sci. USA 69, 143146.
  • Chen, B.M., Chen, J.Y., Kao, M., Lin, J.B., Yu, M.H., and Roffler, S.R. (2000). Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy. Gynecol. Oncol. 79, 272280.
  • Cho, E.Y., Choi, Y.L., Han, J.J., Kim, K.M., and Oh, Y.L. (2008). Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol. Int. 58, 1725.
  • Cimino, D., Fuso, L., Sfiligoi, C. et al. (2008). Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. Int. J. Cancer 123, 13271338.
  • Clarke, D.J., and Lane, A. (2009). Introduction: emerging themes in DNA topoisomerase research. Methods Mol. Biol. 582, 19.
  • Coleman, L.W., Perkins, S.L., Bronstein, I.B., and Holden, J.A. (2000). Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas. Hum. Pathol. 31, 728733.
  • Collins, C., Rommens, J.M., Kowbel, D. et al. (1998). Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc. Natl. Acad. Sci. USA 95, 87038708.
  • Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 21352147.
  • Daud, A.I., Dawson, J., DeConti, R.C. et al. (2009). Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin. Cancer Res. 15, 24792487.
  • Davies, H., Bignell, G.R., and Cox, C. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949954.
  • Dong, J., Phelps, R.G., Qiao, R., Yao, S., Benard, O., Ronai, Z., and Aaronson, S.A. (2003). BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63, 38833885.
  • Ferraz, J.M., Zinzindohoué, F., Lecomte, T., Cugnenc, P.H., Loriot, M.A., Beaune, P., Stücker, I., Berger, A., and Laurent-Puig, P. (2004). Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer. Int. J. Cancer 110, 183187.
  • Fukushige, S., Waldman, F.M., Kimura, M., Abe, T., Furukawa, T., Sunamura, M., Kobari, M., and Horii, A. (1997). Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 19, 161169.
  • Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117122.
  • Gemignani, M.L., Schlaerth, A.C., Bogomolniy, F., Barakat, R.R., Lin, O., Soslow, R., Venkatraman, E., and Boyd, J. (2003). Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol. Oncol. 90, 378381.
  • Gremel, G., Rafferty, M., Lau, T.Y., and Gallagher, W.M. (2009). Identification and functional validation of therapeutic targets for malignant melanoma. Crit. Rev. Oncol. Hematol. 72, 194214.
  • Gupta, M., Fujimori, A., and Pommier, Y. (1995). Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta 1262, 114.
  • Gupta, R., Dastane, A.M., Forozan, F., Riley-Portuguez, A., Chung, F., Lopategui, J., and Marchevsky, A.M. (2009). Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod. Pathol. 22, 128133.
  • Hasle, H., Olsen, J.H., Hansen, J., Friedrich, U., and Tommerup, N. (1998). Occurrence of cancer in a cohort of 183 persons with constitutional chromosome 7 abnormalities. Cancer Genet. Cytogenet. 105, 3942.
  • Hrdlicková, R., Nehyba, J., and Humphries, E.H. (1994). In vivo evolution of c-rel oncogenic potential. J. Virol. 68, 23712382.
  • Huang, C.H., and Treat, J. (2001). New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors. Oncology 61(Suppl. 1), 1424.
  • Humbert, N., Martien, S., Augert, A., Da Costa, M., Mauen, S., Abbadie, C., de Launoit, Y., Gil, J., and Bernard, D. (2009). A genetic screen identifies topoisomerase 1 as a regulator of senescence. Cancer Res. 69, 41014106.
  • Jenkins, R.B., Qian, J., Lee, H.K. et al. (1998). A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res. 58, 759766.
  • Kallioniemi, A., Kallioniemi, O.P., Piper, J., Tanner, M., Stokke, T., Chen, L., Smith, H.S., Pinkel, D., Gray, J.W., and Waldman, F.M. (1994). Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl. Acad. Sci. USA 91, 21562160.
  • Kallioniemi, A., Kallioniemi, O.P., Citro, G., Sauter, G., DeVries, S., Kerschmann, R., Caroll, P., and Waldman, F. (1995). Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 12, 213219.
  • Kirkwood, J.M., Ibrahim, J.G., Sosman, J.A., Sondak, V.K., Agarwala, S.S., Ernstoff, M.S., and Rao, U. (2001). High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19, 23702380.
  • Koul, A., Willén, R., Bendahl, P.O., Nilbert, M., and Borg, A. (2002). Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 94, 23692379.
  • Koynova, D.K., Jordanova, E.S., Milev, A.D., Dijkman, R., Kirov, K.S., Toncheva, D.I., and Gruis, N.A. (2007). Gene-specific fluorescence in-situ hybridization analysis on tissue microarray to refine the region of chromosome 20q amplification in melanoma. Melanoma Res. 17, 3741.
  • Kreditor, M., Fink, M., and Hochster, H.S. (2005). Recent developments in the clinical activity of topoisomerase-1 inhibitors. Cancer Chemother. Biol. Response Modif. 22, 61100.
  • Kretzschmar, M., Meisterernst, M., and Roeder, R.G. (1993). Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc. Natl. Acad. Sci. USA 90, 1150811512.
  • Lang, J., and MacKie, R.M. (2005). Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J. Invest. Dermatol. 125, 575579.
  • Larsen, A.K., and Gobert, C. (1999). DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde? Pathol. Oncol. Res. 5, 171178.
  • Levy, C., Khaled, M., and Fisher, D.E. (2006). MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12, 406414.
  • Li, T.K., and Liu, L.F. (2001). Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 41, 5377.
  • Lin, W.M., Baker, A.C., and Beroukhim, R. (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68, 664673.
  • Lynch, B.J., Komaromy-Hiller, G., Bronstein, I.B., and Holden, J.A. (1998). Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma. Hum. Pathol. 29, 12401245.
  • Merino, A., Madden, K.R., Lane, W.S., Champoux, J.J., and Reinberg, D. (1993). DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365, 227232.
  • Miao, Z.H., Player, A., and Shankavaram, U. (2007). Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res. 67, 87528761.
  • Mondal, N., Zhang, Y., Jonsson, Z., Dhar, S.K., Kannapiran, M., and Parvin, J.D. (2003). Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity. Nucleic Acids Res. 31, 50165024.
  • Moore, S.R., Persons, D.L., Sosman, J.A. et al. (2008). Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin. Cancer Res. 14, 29272935.
  • Morinaga, R., Okamoto, I., Fujita, Y., Arao, T., Sekijima, M., Nishio, K., Ito, H., Fukuoka, M., Kadota, J., and Nakagawa, K. (2008). Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. Cancer Sci. 99, 24552460.
  • Nambiar, S., Mirmohammadsadegh, A., and Hengge, U.R. (2008). Cutaneous melanoma: fishing with chips. Curr. Mol. Med. 8, 235243.
  • Planas-Silva, M.D., Shang, Y., Donaher, J.L., Brown, M., and Weinberg, R.A. (2001). AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res. 61, 38583862.
  • Pollock, P.M., Welch, J., and Hayward, N.K. (2001). Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res. 61, 11541161.
  • Poynter, J.N., Elder, J.T., Fullen, D.R., Nair, R.P., Soengas, M.S., Johnson, T.M., Redman, B., Thomas, N.E., and Gruber, S.B. (2006). BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 16, 267273.
  • Rákosy, Z., Vízkeleti, L., Ecsedi, S. et al. (2007). EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int. J. Cancer 121, 17291737.
  • Rákosy, Z., Vízkeleti, L., Ecsedi, S., Bégány, A., Emri, G., Adány, R., and Balázs, M. (2008). Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 182, 116121.
  • Ramos, J.C., Ruiz, P. Jr., Ratner, L. et al. (2007). IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood 109, 30603068.
  • Ried, T., Knutzen, R., Steinbeck, R., Blegen, H., Schröck, E., Heselmeyer, K., du Manoir, S., and Auer, G. (1996). Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer 15, 234245.
  • Rodriguez, F.J., Scheithauer, B.W., Giannini, C., Bryant, S.C., Jenkins, R.B. et al. (2008). Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer 113, 27792789.
  • Romieu-Mourez, R., Kim, D.W., Shin, S.M., Demicco, E.G., Landesman-Bollag, E., Seldin, D.C., Cardiff, R.D., and Sonenshein, G.E. (2003). Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol. Cell. Biol. 23, 57385754.
  • Shykind, B.M., Kim, J., Stewart, L., Champoux, J.J., and Sharp, P.A. (1997). Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev. 11, 397407.
  • Stark, M., and Hayward, N. (2007). Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67, 26322642.
  • Strömberg, S., Agnarsdóttir, M., and Magnusson, K. (2009). Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma. J. Proteome Res. 8, 16391646.
  • Suzuki, T., Maruno, M., Wada, K., Kagawa, N., Fujimoto, Y., Hashimoto, N., Izumoto, S., and Yoshimine, T. (2004). Genetic analysis of human glioblastomas using a genomic microarray system. Brain Tumor Pathol 21, 2734.
  • Swisher, E.M., Peiffer-Schneider, S., Mutch, D.G., Herzog, T.J., Rader, J.S., Elbendary, A., and Goodfellow, P.J. (1999). Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer 85, 119126.
  • Thomas, N.E., Alexander, A., Edmiston, S.N., Parrish, E., Millikan, R.C., Berwick, M., Groben, P., Ollila, D.W., Mattingly, D., and Conway, K. (2004). Tandem BRAF mutations in primary invasive melanomas. J. Invest. Dermatol. 122, 12451250.
  • Thomas, R.K., Baker, A.C., Debiasi, R.M. et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347351.
  • Tsao, H., Atkins, M.B., and Sober, A.J. (2004). Management of cutaneous melanoma. N. Engl. J. Med. 351, 9981012.
  • Udart, M., Utikal, J., Krähn, G.M., and Peter, R.U. (2001). Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 3, 245254.
  • Wong, L.J., Dai, P., Lu, J.F., Lou, M.A., Clarke, R., and Nazarov, V. (2006). AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines. BMC Cancer 6, 111.
  • Zhang, L., Huang, J., Yang, N., Greshock, J. et al. (2006). microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA 103, 91369141.